文献速递泌尿生殖MRUS

前列腺扩展系统六分区穿刺与MR/TRUS融合靶向穿刺的组织病理学与多参数MRI空间映射对照研究

Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate.
PubMed 文献 · Eur Radiol · 2018-10-16

研究对316例疑似临床显著前列腺癌(sPC)患者行24针经会阴系统穿刺及PI-RADS≥3的MR病灶六分区映射,以联合系统与靶向穿刺为金标准。MRI识别sPC患者敏感度0.97、阴性预测值0.91,但18%的sPC位于MRI映射区域之外。

要点

  • MRI识别sPC患者敏感度0.97、特异度0.22、阳性预测值0.43、阴性预测值0.91。
  • 六分区层面敏感度0.73、特异度0.38、阳性预测值0.26、阴性预测值0.93。
  • 18%的sPC位于mpMRI映射区域之外,即使考虑10 mm安全边界仍存在。

核心结论

  • mpMRI空间映射与组织病理学一致性较好,患者层面敏感度和阴性预测值极佳、特异度和阳性预测值可接受,但18%的sPC位于mpMRI映射区域外,量化了MRI完整定位病变范围的局限。

研究设计与样本

  • 316例疑似sPC患者行24针经会阴系统穿刺六分区sPC(ISUP组≥2)映射及PI-RADS评分≥3的MR病灶映射,金标准为联合系统穿刺(中位23针)与靶向穿刺。

关键影像表现/征象

  • 121例sPC患者中4例(3%)MRI阴性,MRI正确识别117/121(97%)例sPC患者。
  • 117例MRI阳性sPC患者中96例(82%)mpMRI未遗漏额外sPC,21例(18%)存在MRI阴性sPC病灶。
  • 1896个六分区中379个(20%)含sPC,MR阳性六分区sPC检出率26%(337/1275),MR阴性六分区为7%(42/621)。

诊断标准与关键数值

  • 患者层面:敏感度0.97、特异度0.22、阳性预测值0.43、阴性预测值0.91。
  • 六分区层面:敏感度0.73、特异度0.38、阳性预测值0.26、阴性预测值0.93。
  • sPC定义为ISUP组≥2;MRI病灶定义为PI-RADS评分≥3。

临床应用与阅片要点

  • 在观察到的sPC患病率下,患者层面mpMRI敏感度和阴性预测值极佳、特异度和阳性预测值可接受,支持其用于活检前检测可疑病灶。
  • 目前不推荐仅依据MRI映射制定前列腺局灶治疗计划,因相当数量病例的sPC可能未被治疗。
  • 尽管整体性能极佳,18%的sPC位于mpMRI映射区域外(即使考虑10 mm安全边界),提示前列腺MRI完整映射全部癌灶能力有限。

局限性

  • 18%的sPC位于mpMRI映射区域外,即使考虑10 mm安全边界仍存在,量化了MRI完整定位病变范围的局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: MRI has limited ability to detect multifocal disease or the full extent of prostate involvement with clinically significant prostate cancer (sPC). We compare the spatial co-localization at sextant resolution of MRI lesions and histopathological mapping by combined targeted and extended systematic biopsies.

MATERIALS AND METHODS: Sextants were mapped for sPC (ISUP group ≥ 2) by 24-core transperineal systematic biopsies in 316 patients with suspicion for sPC and by MR lesions of PI-RADS score of ≥ 3. The gold standard is combined systematic (median 23 cores) and targeted biopsies.

RESULTS: Of 316 men, 121 (38%) harbored sPC. Of these 121 patients, 4 (3%) had a negative MRI. MRI correctly identified 117/121 (97%) patients with sPC. In these patients, mpMRI missed no additional sPC in 96 (82%), while MRI-negative sPC lesions were present in 21 patients (18%). Of 1896 sextants, 379 (20%) harbored sPC. MR-positive sextants contained sPC in 26% (337/1275), compared to 7% (42/621) in MR-negative sextants. On a patient basis, sensitivity was 0.97, specificity 0.22, positive predictive value 0.43, and negative predictive value 0.91. On a sextant basis, sensitivity was 0.73, specificity 0.38, positive predictive value 0.26, and negative predictive value 0.93.

CONCLUSION: MpMRI mapping agreed well with histopathology with, at the observed sPC prevalence and on a patient basis, excellent sensitivity and negative predictive value, and acceptable specificity and positive predictive value for sPC. However, 18% of sPC was outside the mpMRI mapped region, quantifying limitations of MRI for complete localization of disease extent.

KEY POINTS: • Currently, exclusive MRI mapping of the prostate for focal treatment planning cannot be recommended, as significant prostate cancer may remain untreated in a substantial number of cases. • At the observed sPC prevalence and on a patient basis, mpMRI has excellent sensitivity and NPV, and acceptable specificity and PPV for detection of prostate cancer, supporting its use to detect suspicious lesions before biopsy. • Despite the excellent global performance, 18% of sPC was outside the mpMRI mapped region even when a security margin of 10 mm was considered, indicating that prostate MRI has limited ability to completely map all cancer foci within the prostate.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Bonekamp D, Schelb P, Wiesenfarth M, et al. Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate. Eur Radiol. 2018. PMID: 30327861. doi:10.1007/s00330-018-5751-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。